The impact of shrunken pore syndrome in patient with rheumatic diseases on bone mineral metabolism

References

• Grubb A. Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: simultaneous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and an internal quality check. Scand J Clin Lab Invest. 2010;70(2):65–70.
   PubMed Web of Science ®Google Scholar
• Grubb A, Nyman U, Björk J. Improved estimation of glomerular filtration rate (GFR) by comparison of eGFRcystatin C and eGFRcreatinine. Scand J Clin Lab Invest. 2012;72(1):73–77.
   PubMed Web of Science ®Google Scholar
• Björk J, Grubb A, Larsson A, et al. Accuracy of GFR estimating equations combining standardized cystatin C and creatinine assays: a cross-sectional study in Sweden. Clin Chem Lab Med. 2015;53:403–414.
   PubMed Web of Science ®Google Scholar
• Grubb A, Lindström V, Jonsson M, et al. Reduction in glomerular pore size is not restricted to pregnant women. evidence for a new syndrome: ‘shrunken pore syndrome'. Scand J Clin Lab Invest. 2015;75(4):333–340.
   PubMed Web of Science ®Google Scholar
• Miner JH. Glomerular basement membrane composition and the filtration barrier. Pediatr Nephrol. 2011;26(9):1413–1417.
   PubMed Web of Science ®Google Scholar
• Salgado JV, Neves FA, Bastos MG, et al. Monitoring renal function: measured and estimated glomerular filtration rates – a review. Braz J Med Biol Res. 2010;43(6):528–536.
   PubMed Web of Science ®Google Scholar
• Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451–487.
   PubMed Web of Science ®Google Scholar
• Zhou H, Yang M, He X, et al. eGFR, cystatin C and creatinine in shrunken pore syndrome. Clin Chim Acta. 2019;498:1–5.
   PubMed Web of Science ®Google Scholar
• Grubb A. Shrunken pore syndrome – a new syndrome. 2019. Sweden: Lakartidningen.
   Google Scholar
• Almén MS, Björk J, Nyman U, et al. Shrunken pore syndrome is associated with increased levels of atherosclerosis-promoting proteins. Kidney Int Rep. 2019;4(1):67–79.
   PubMed Web of Science ®Google Scholar
• Grubb A. Shrunken pore syndrome – a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options. Clin Biochem. 2020;13: 12–20.
   Google Scholar
• Dardashti A, Nozohoor S, Grubb A, et al. Shrunken pore syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting. Scand J Clin Lab Invest. 2016;76(1):74–81.
   PubMed Web of Science ®Google Scholar
• Herou E, Dardashti A, Nozohoor S, et al. The mortality increase in cardiac surgery patients associated with shrunken pore syndrome correlates with the eGFRcystatin c/eGFRcreatinine-ratio. Scand J Clin Lab Invest. 2019;79(3):167–173.
   PubMed Web of Science ®Google Scholar
• Ljungberg J, Johansson B, Bergdahl IA, et al. Mild impairment of renal function (shrunken pore syndrome) is associated with increased risk for future surgery for aortic stenosis. Scand J Clin Lab Invest. 2019;79(7):524–530.
   PubMed Web of Science ®Google Scholar
• Waheed S, Matsushita K, Astor BC, et al. Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. CJASN. 2013;8(3):434–442.
   PubMed Web of Science ®Google Scholar
• Purde MT, Nock S, Risch L, et al. The cystatin C/creatinine ratio, a marker of glomerular filtration quality: associated factors, reference intervals, and prediction of morbidity and mortality in healthy seniors. Transl Res. 2016;169:80–90.e1–2.
   PubMed Web of Science ®Google Scholar
• Christensson A, Grubb A, Molvin J, et al. The shrunken pore syndrome is associated with declined right ventricular systolic function in a heart failure population – the HARVEST study. Scand J Clin Lab Invest. 2016;76(7):568–574.
   PubMed Web of Science ®Google Scholar
• Jarquin Campos A, Risch L, Baumann M, et al. Shrunken pore syndrome, preeclampsia, and markers of NO metabolism in pregnant women during the first trimester. Scand J Clin Lab Invest. 2019;20:1–8.
   Google Scholar
• Åkesson A, Lindström V, Nyman U, et al. Shrunken pore syndrome and mortality: a cohort study of patients with measured GFR and known comorbidities. Scand J Clin Lab Invest. 2019;79(1–2):91–98.
   PubMedGoogle Scholar
• Brewer HB, Fairwell T, Ronan R, et al. Human parathyroid hormone: amino-acid sequence of the amino-terminal residues 1-34. Proc Natl Acad Sci USA. 1972;69(12):3585–3588.
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, et al, on behalf of the Collaborators Developing the Japanese Equation for Estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–992.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation Inc. Estimated glomerular filtration rate (eGFR). National Kidney Foundation; 2018 [cited 2020 Jan 11]. Available from: https://www.kidney.org/atoz/content/gfr.
   Google Scholar
• Schnittger S, Rao VG, Abrahamson M, et al. Cystatin C (CST3), the candidate gene for hereditary cystatin C amyloid angiopathy (HCCAA), and other members of the cystatin gene family are clustered on chromosome 20p11.2. Genomics. 1993;16(1):50–55.
   PubMed Web of Science ®Google Scholar
• Bennett MR, Devarajan P. Characteristics of an ideal biomarker of kidney diseases. Biomarkers of Kidney Diseases. Cambridge MA, USA: Academic Press, Elsevier; 2016. p. 12–16.
   Google Scholar
• Knight E, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416–1421.
   PubMed Web of Science ®Google Scholar
• Wasen E, Isoaho R, Mattila K, et al. Serum cystatin C in the aged: relationship with health status. Am J Kidney Dis. 2003;42(1):36–43.
   PubMed Web of Science ®Google Scholar
• Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol. 2011;22(2):216–224.
   PubMed Web of Science ®Google Scholar
• Huang JC, Sakata T, Pfleger LL, et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004;19(2):235–244.
   PubMed Web of Science ®Google Scholar
• De Groot T, Lee K, Langeslag M, et al. Parathyroid hormone activates TRPV5 via PKA-dependent phosphorylation. J Am Soc Nephrol. 2009;20(8):1693–1704.
   PubMed Web of Science ®Google Scholar
• Segawa H, Yamanaka S, Onitsuka A, et al. Parathyroid hormone-dependent endocytosis of renal type IIc Na-Pi cotransporter. Am J Physiol Renal Physiol. 2007;292(1):F395–F403.
   PubMed Web of Science ®Google Scholar
• Halleen JM, Tiitinen SL, Ylipahkala H, et al. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 2006;52(9-10):499–510.
   PubMed Web of Science ®Google Scholar
• Ben Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003–4008.
   PubMed Web of Science ®Google Scholar
• Pearson D, Cawte SA, Green DJ. A comparison of phantoms for cross-calibration of lumbar spine DXA. Osteoporos Int. 2002;13(12):948–954.
   PubMed Web of Science ®Google Scholar
• Tetsuka S, Morita M, Ikeguchi K, et al. Creatinine/cystatin C ratio as a surrogate marker of residual muscle mass in amyotrophic lateral sclerosis. Neurol Clin Neurosci. 2013;1(1):32–37.
   Google Scholar
• Suzuki K, Furuse H, Tsuda T, et al. Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: a retrospective study. J Int Med Res. 2015;43(4):573–582.
   PubMed Web of Science ®Google Scholar
• Harada H, Kai H, Shibata R, et al. New diagnostic index for sarcopenia in patients with cardiovascular diseases. PLOS One. 2017;12(5):e0178123.
   PubMed Web of Science ®Google Scholar
• Kashani K, Sarvottam K, Pereira NL, et al. The sarcopenia index: a novel measure of muscle mass in lung transplant candidates. Clin Transplant. 2018;32(3):e13182.
   PubMed Web of Science ®Google Scholar
• Osaka T, Hamaguchi M, Hashimoto Y, et al. Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;139:52–58.
   PubMed Web of Science ®Google Scholar
• Yoshii I, Chijiwa T, Sawada N. Screening osteoporotic femoral neck without measuring bone mineral density with the use of tartrate resistant acid phosphatase-5b and serum-creatinine-to-cystatin C ratio in Japanese postmenopausal women. J Orthop Sci. 2020;25(4):671–676.
   PubMed Web of Science ®Google Scholar